TD Cowen lowered the firm’s price target on HCA Healthcare (HCA) to $377 from $440 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q4 report. HCA reported a slight revenue and EBITDA beat combined with tight labor management, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare price target lowered to $384 from $405 at RBC Capital
- HCA Healthcare price target lowered to $370 from $380 at BofA
- HCA Healthcare price target lowered to $366 from $392 at Barclays
- HCA Healthcare Reports Strong Q4 2024 Results
- HCA Recovers from $200 Million Hurricane Hit to Beat Q4 Forecasts